Table 4.
Independent variables | HRCT | |||
---|---|---|---|---|
Enter | Forward Stepwise | |||
β | P value | β | P value | |
Ground-glass score | ||||
Age, years | 0.026 | 0.85 | — | Not in the model |
Disease duration, years | 0.068 | 0.90 | — | Not in the model |
DAS28 | 0.851 | 0.53 | — | Not in the model |
Anti-CCP2 titers | 0.048 | 0.03 | 0.053 | 0.02 |
MTX treatment duration, years | −0.299 | 0.85 | — | Not in the model |
Fibrosis score | ||||
Age, years | −0.069 | 0.19 | — | Not in the model |
Disease duration, years | −0.510 | 0.01 | −0.506 | 0.01 |
DAS28 | 0.430 | 0.41 | — | Not in the model |
Anti-CCP2 titers | 0.065 | <0.001 | 0.070 | <0.001 |
MTX treatment duration, years | 0.879 | <0.001 | 1.035 | <0001 |
Anti-CCP2 titers: anti-cyclic citrullinated peptide antibodies titers (second generation); DAS28: disease activity score; HAQ-Di: Health Assessment Questionnaire; MTX: methotrexate. Dependent variables: first model: ground-glass score, second model: fibrosis score. Covariates included in this analysis were those quantitative variables that had statistical significance in the univariate analysis or were considered with biologic plausibility to explain the severity of ILD in HRCT.